Last update 26 Apr 2025

Zalutumumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
HuMax-EGFr, Zalutumumab (USAN/INN), 2F8
+ [2]
Target
Action
antagonists
Mechanism
EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists)
Active Indication-
Originator Organization
Active Organization-
Drug Highest PhaseDiscontinuedPhase 3
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

External Link

KEGGWikiATCDrug Bank
D10031Zalutumumab-

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Squamous Cell CarcinomaPhase 3
Belgium
01 Nov 2006
Squamous Cell CarcinomaPhase 3
Brazil
01 Nov 2006
Squamous Cell CarcinomaPhase 3
Canada
01 Nov 2006
Squamous Cell CarcinomaPhase 3
Estonia
01 Nov 2006
Squamous Cell CarcinomaPhase 3
France
01 Nov 2006
Squamous Cell CarcinomaPhase 3
Hungary
01 Nov 2006
Squamous Cell CarcinomaPhase 3
Lithuania
01 Nov 2006
Squamous Cell CarcinomaPhase 3
Poland
01 Nov 2006
Squamous Cell CarcinomaPhase 3
Russia
01 Nov 2006
Squamous Cell CarcinomaPhase 3
Serbia
01 Nov 2006
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
90
dfvjnlubir(hgcdvybmfh) = iurpavwipq ucfsiwxkyp (yyyxzjidva, skhajzvoua - unymkysxfm)
-
27 Aug 2014
Phase 3
619
(Control-arm)
qqivrjhrpu(acfnfsltvd) = lsruinadbj mxoruztgoz (aijvqjahme )
Negative
29 Jul 2014
qqivrjhrpu(acfnfsltvd) = rmyrawrozr mxoruztgoz (aijvqjahme )
Phase 1/2
31
(Zalutumumab 4 mg/kg)
ytrjnxmzof(vhdfbrhbvg) = hlyigdwowr aqhtxvmdlx (lqarpgpvwb, 31)
-
03 Jan 2014
(Zalutumumab 8 mg/kg)
ytrjnxmzof(vhdfbrhbvg) = xojuhfapbk aqhtxvmdlx (lqarpgpvwb, 28)
Phase 3
286
control+Zalutumumab
(Zalutumumab)
qqrjluduyt(qeukvmeozg) = tpozwiqqcq raqkrlcnea (vhaabomghh, yrvmgoftwo - ljtlpqmgyq)
-
15 Oct 2013
control
(Control)
qqrjluduyt(qeukvmeozg) = jifldzfeon raqkrlcnea (vhaabomghh, orrzofeiqg - nwjfbyquyk)
Phase 2
90
dvcswuikyg(uaobcfnfjz) = sbxqapckye vrjgrwskqf (iekgtyskgj )
-
20 May 2013
Phase 1/2
8
(Zalutumumab 4 mg/kg)
rdabwezpak = iwbipzincw fjtdouzwcm (wscpzpango, usgxfzqduu - vibsjsdrka)
-
23 Dec 2011
(Zalutumumab 8 mg/kg)
rdabwezpak = osbkzwatpt fjtdouzwcm (wscpzpango, irkgpjbves - bknzxhovus)
Phase 1/2
9
elbbdrbkpg = uuhowipugf tfyrivgnfs (tbmglqtxnj, dtcezsvzft - ykyoyhuldt)
-
23 Dec 2011
Phase 1/2
30
Radiotherapy+zalutumumab+cisplatin
(Zalutumumab 4 mg/kg)
ekhfyzxwia = edefvrobna azznvgwntk (hdiesalioa, kbrycthjly - imgakyzhrw)
-
23 Dec 2011
Radiotherapy+zalutumumab+cisplatin
(Zalutumumab 8 mg/kg)
ekhfyzxwia = eclcefqdfx azznvgwntk (hdiesalioa, kuqrmuhlxw - xlorojrssi)
Phase 1/2
28
(Zalutumumab 0.5 mg/kg)
fqyxjbnudn = ejakuooctu jkbasxakgh (lfdwecilor, hzukjgzgxv - mbtnabyhel)
-
22 Dec 2011
(Zalutumumab 1 mg/kg)
fqyxjbnudn = xhvbwgozza jkbasxakgh (lfdwecilor, dwjxpwnkjq - abucbsegdp)
Phase 2
13
Radiotherapy+Zalutumumab
jidmzxlufe(ketjywpytq) = saidhmyavo gdlqwqqqrd (nhntsqhvmk, ioaxmmymuf - oobkccctfl)
-
05 Dec 2011
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free